All of the following are rare but life-threatening adverse effects of thioamide group of anti-thyroid drugs except:
**Core Concept**
Thioamide group of anti-thyroid drugs, such as methimazole and propylthiouracil, are used to treat hyperthyroidism by inhibiting thyroid hormone synthesis. However, they can cause rare but severe adverse effects due to their potential to induce agranulocytosis, hepatotoxicity, and other idiosyncratic reactions.
**Why the Correct Answer is Right**
Agranulocytosis is a potentially life-threatening condition characterized by a severe decrease in white blood cells, making patients susceptible to infections. Hepatotoxicity, on the other hand, involves liver damage, which can lead to jaundice, liver failure, and even death. **Aplastic anemia**, another rare but life-threatening adverse effect, involves bone marrow failure, resulting in a decrease in all blood cell types.
**Why Each Wrong Option is Incorrect**
**Option A:** **Lupus-like syndrome** is not a rare but life-threatening adverse effect of thioamide group of anti-thyroid drugs. While these medications can induce various autoimmune reactions, lupus-like syndrome is not typically associated with them.
**Option B:** **Hepatotoxicity** is indeed a rare but life-threatening adverse effect of thioamide group of anti-thyroid drugs, as mentioned earlier.
**Option C:** **Agranulocytosis** is also a correct answer, as it is a well-documented, life-threatening adverse effect of thioamide group of anti-thyroid drugs.
**Option D:** **Pernicious anemia** is not a rare but life-threatening adverse effect of thioamide group of anti-thyroid drugs. Pernicious anemia is a separate condition caused by a lack of intrinsic factor, leading to vitamin B12 deficiency.
**Clinical Pearl / High-Yield Fact**
It is essential to monitor patients taking thioamide group of anti-thyroid drugs for signs of agranulocytosis, hepatotoxicity, and other idiosyncratic reactions, such as fever, jaundice, and unexplained infections.
**Correct Answer: A. Lupus-like syndrome.**